Literature DB >> 7216495

Immunization of chimpanzees with hepatitis B virus-derived polypeptides.

G R Dreesman, F B Hollinger, Y Sanchez, P Oefinger, J L Melnick.   

Abstract

Previous studies established that the purified polypeptides derived from the 22-nm particles associated with hepatitis B surface antigen (HBsAg) produce both humoral and cellular immunity against HBsAg in guinea pigs. Therefore, the two major polypeptides with molecular weights of 22,000 and 25,000 (P22 and P25, respectively) were isolated, adsorbed to an alum adjuvant, and used to immunize four nonimmune chimpanzees. A vigorous anti-HBs response was observed in all four animals after one inoculation of an alum-adsorbed polypeptide vaccine containing 40 micrograms of protein. After one to two booster inoculations, anti-HBs switched from being predominantly immunoglobulin M to the immunoglobin G class, indicating the establishment of immunological memory. Challenge of the vaccinated chimpanzees with 30,000 chimpanzee infectious doses of hepatitis B virus provided evidence for the efficacy of this vaccine. None of the four animals developed serological markers associated with an active hepatitis B infection, and no biochemical or histopathological changes of hepatitis were observed. A nonvaccinated control chimpanzee that was inoculated with the same hepatitis B virus material developed hepatitis B infection, confirming infectivity of the challenge inoculum.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7216495      PMCID: PMC350587          DOI: 10.1128/iai.32.1.62-67.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Cell-mediated immunity in guinea pigs to subunits derived from hepatitis B surface antigen.

Authors:  G A Cabral; R Chairez; F Marciano-Cabral; M Suarez; G R Dreesman; J L Melnick; F B Hollinger
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

2.  Biophysical properties of purified morphologic forms of hepatitis B antigen.

Authors:  R Chairez; F B Hollinger; J L Melnick; G R Dreesman
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

3.  A prospective study indicating that double-antibody radioimmunoassay reduces the incidence of post-transfusion hepatitis B.

Authors:  F B Hollinger; J Werch; J L Melnick
Journal:  N Engl J Med       Date:  1974-05-16       Impact factor: 91.245

4.  Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention.

Authors:  S Krugman; J P Giles
Journal:  N Engl J Med       Date:  1973-04-12       Impact factor: 91.245

5.  Characterization of antibodies to the structural polypeptides of HGSAg: evidence for subtype-specific determinants.

Authors:  J W Gold; J W Shih; R H Purcell; J L Gerin
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

6.  Production of antibody to individual polypeptides derived from purified hepatitis B surface antigen.

Authors:  G R Dreesman; R Chairez; M Suarez; F B Hollinger; R J Courtney; J L Melnick
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

7.  Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees.

Authors:  R H Purcell; J L Gerin
Journal:  Am J Med Sci       Date:  1975 Sep-Oct       Impact factor: 2.378

8.  Hepatitis B virus infection in chimpanzees: titration of subtypes.

Authors:  L F Barker; J E Maynard; R H Purcell; J H Hoofnagle; K R Berquist; W T London; R J Gerety; D H Krushak
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

9.  Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats.

Authors:  G R Dreesman; F B Hollinger; R M McCombs; J L Melnick
Journal:  Infect Immun       Date:  1972-02       Impact factor: 3.441

10.  Hepatitis B surface antigen produced by a human hepatoma cell line.

Authors:  G M MacNab; J J Alexander; G Lecatsas; E M Bey; J M Urbanowicz
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

View more
  4 in total

1.  Inhibition of a common human anti-hepatitis B surface antigen idiotype by a cyclic synthetic peptide.

Authors:  R C Kennedy; G R Dreesman; J T Sparrow; A R Culwell; Y Sanchez; I Ionescu-Matiu; F B Hollinger; J L Melnick
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

Review 2.  Priorities for immunisation against hepatitis B.

Authors:  A J Zuckerman
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-06

3.  New hepatitis B vaccines.

Authors:  A J Zuckerman
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-16

4.  Perinatal transmission of hepatitis B virus.

Authors:  R K Chaudhary
Journal:  Can Med Assoc J       Date:  1983-03-15       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.